<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01418729</url>
  </required_header>
  <id_info>
    <org_study_id>ESTAHEP-2010</org_study_id>
    <secondary_id>2010-024421-21</secondary_id>
    <nct_id>NCT01418729</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma</brief_title>
  <acronym>ESTAHEP-2010</acronym>
  <official_title>Phase-II, Multicenter, Randomized, Double-Blind, Parallel-Group Trial to Compare the Efficacy and Safety of Sorafenib Plus Pravastatin Against Sorafenib Plus Placebo in Patients With Advanced Hepatocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Donostia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSTITUTO BIODONOSTIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Donostia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the overall survival (OS) in order to assess the
      efficacy and safety of pravastatin as adjuvant treatment to sorafenib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the overall survival (OS) in order to assess the efficacy and safety of pravastatin as adjuvant treatment to sorafenib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the time to progression (TTP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to symptomatic progression (TTSP).</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the time to symptomatic progression (TTSP).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Advanced Hepatocarcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib plus Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The treatment received will be sorafenib 400 mg/12 h + placebo/24 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Treatment:
Patients will be randomized in two groups, A and B:
Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.
Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.</description>
    <arm_group_label>Sorafenib plus Pravastatin</arm_group_label>
    <arm_group_label>Sorafenib plus Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have been diagnosed with advanced hepatocarcinoma (HCC), confirmed
             histologically or with non-invasive criteria, according to the clinical practice
             guidelines by the American Association for the Study of Liver Diseases (AASLD) during
             a maximum period of 15 days prior to the baseline visit.

          -  Males and females, over 18 years of age.

          -  Patients who have not previously received treatment with sorafenib.

          -  Have an ECOG ≤ 2.

          -  Liver function: Child A and B7.

          -  Life expectancy greater than 12 weeks.

          -  Adequate kidney function: serum creatinine concentration less than or equal to 1.5
             times the upper limit of normal (ULN).

          -  Sign the written informed consent before starting any procedure, including
             randomization.

        Exclusion Criteria:

          -  Patients who routinely (more than 3 times a week) take some sort of statin.

          -  Patients with hypersensitivity to statins.

          -  Pregnant or breastfeeding women.

          -  Peripheral neuropathy: grade 2 or higher

          -  Patients who have been diagnosed, within the previous 5 years, with another type of
             tumor, except for non-melanoma skin cancer, or in situ carcinoma of the cervix or the
             urinary bladder.

          -  Patients receiving chemotherapy or radiotherapy for another type of tumor.

          -  Patients with heart failure greater than NYHA grade II, hypertension that is
             uncontrolled with medication, uncontrolled arrhythmias or AMI within the previous six
             months.

          -  A history of perforation or hemorrhage due to a gastroduodenal ulcus within the last
             month.

          -  Greater hemorrhagic diseases.

          -  Asthmatic patients uncontrolled with medication.

          -  Any other contraindication associated to the use of statins.

          -  Physical or psychological inability to participate in the trial.

          -  Treatment with another investigational drug or participation in another clinical trial
             within 6 months prior to inclusion in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan I Arenas, MD,PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Donostia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Bustamante Scheneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Cruces</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trinidad Serrano Aullo, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercedes Iñarrairaegui Bastarrica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Blanco Sampascual, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Basurto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Varela, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Central de Asturias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar Nuñez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Infanta Sofia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Donostia, Instituto Biodonostia</name>
      <address>
        <city>San Sebastian</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.biodonostia.org</url>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Donostia</investigator_affiliation>
    <investigator_full_name>Juan I. Arenas Ruiz-Tapiador</investigator_full_name>
    <investigator_title>MD. PHD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

